Casi Pharmaceuticals Inc Stock Price, News & Analysis

CASI Pharmaceuticals (Nasdaq: CASI) announced that Juventas Cell Therapy Ltd. has successfully raised over RMB410 million (approximately $63 million) in a Series C financing round. The funds will be utilized for a new drug application in China and to advance commercialization and research for CNCT19. CASI holds a 12.0098% equity stake in Juventas and aims to co-commercialize CNCT19, a CAR-T therapy targeting CD19 for treating B-cell malignancies. This collaboration emphasizes CASI's commitment to enhancing hematology-oncology therapy access in China.

CASI Pharmaceuticals, Inc. (Nasdaq: CASI) announced that Dr. Alexander Zukiwski, Chief Medical Officer, will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, 2021, at 12:05 PM (EDT). The presentation will be accessible via CASI's website under 'Events & Presentations', with archived replays available for 90 days. CASI is focused on developing therapeutics in hematology oncology and expanding its reach into global markets, especially China, leveraging its regulatory and commercial expertise.

CASI Pharmaceuticals reported strong financial results for Q2 2021, generating $7.1 million in EVOMELA revenues, a 173% increase from Q2 2020. The company revised its full-year revenue growth guidance to exceed 80% over 2020. The Phase 1 clinical trial for CID-103 has commenced, alongside promising developments in CNCT19 and ongoing patent activities with BioInvent. Despite a net loss of $6.7 million, cash and equivalents stand at $60.4 million, reflecting a strong liquidity position.

CASI Pharmaceuticals (Nasdaq: CASI) announced a conference call to discuss its second quarter highlights on August 12, 2021, at 8:00 a.m. ET. The call will provide insights from the Chairman & CEO regarding the company's business updates and future milestones. Investors can join the call using specific dialing options for different regions. CASI focuses on developing innovative therapeutics, particularly in hematology oncology, aiming to expand its market presence in China and globally. More details are available on their official website.

CASI Pharmaceuticals announced the first patient dosing in a Phase 1 clinical trial evaluating CID-103, an innovative anti-CD38 monoclonal antibody for relapsed or refractory multiple myeloma. This study aims to assess CID-103's safety, tolerability, and clinical activity. Preclinical data indicated promising efficacy and favorable safety compared to existing treatments. The Company is optimistic about CID-103's potential to provide significant patient benefits and accelerate its development path.

CASI Pharmaceuticals, a U.S. biopharmaceutical company, announced that Dr. Wei-Wu He will present at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 9:30 AM (EST). The event will showcase the company’s focus on developing therapeutics in hematology oncology and other unmet medical needs. A webcast will be available on CASI's website in the 'Investors Relations' section, with replays for 30 days post-event. CASI aims to leverage its expertise in China and the U.S. to become a leader in the biopharmaceutical industry.

CASI Pharmaceuticals reported a revenue of $5.7 million from EVOMELA for Q1 2021, up from $3.4 million in Q1 2020, with a projected annual growth exceeding 50%. R&D expenses increased to $5.3 million mainly due to the CID-103 project. General and administrative costs rose to $5.5 million, reflecting expanded operations. The net loss for the quarter widened to $13.7 million, compared to $8.2 million in the previous year. The firm raised $32.5 million in capital to enhance its balance sheet.

CASI Pharmaceuticals (Nasdaq: CASI) announced it will host a conference call on May 13, 2021, at 8:00 a.m. ET to review its first quarter highlights. The call will be led by the company's Chairman & CEO, discussing business updates and upcoming milestones. Interested participants can access the call by dialing the relevant numbers for the U.S., China, or Hong Kong, with a conference ID of 7478587. A replay of the call will also be available. CASI focuses on developing therapeutics for hematology oncology and has a significant presence in the Chinese market.

CASI Pharmaceuticals reported its 2020 financial results, disclosing revenue of $15 million, up from $4.1 million in 2019, primarily driven by the sales of EVOMELA. The company forecasted over 50% revenue growth in 2021. It completed a public offering raising $32.5 million and highlighted in-licensing of a VCP/p97 inhibitor for treatment of hematological malignancies. However, net loss increased to $47.5 million from $45.4 million due to rising R&D and acquisition costs. The company is focused on expanding its U.S. investor base while preparing for regulatory filings in China.